The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
Year: 2015
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Gautam Borthakur, Yishai Ofran, Arnon Nagler, Jacob M. Rowe, James M. Foran, Geoffrey L. Uy, John F. DiPersio, Jessica K. Altman, Olga Frankfurt, Martin S Tallman, Amnon Peled, Yaron Pereg, Abi Vainstein, Arnon Aharon, Ahmed AlRawi, Teresa McQueen, Naveen Pemmaraju, Carlos E. Bueso-Ramos, Jorge E. Cortes, Michael Andreeff
Institutions: The University of Texas MD Anderson Cancer Center, Rambam Health Care Campus, Tel Aviv University, Sheba Medical Center, Shaare Zedek Medical Center, Bikur Cholim Hospital, Mayo Clinic, Mayo Clinic in Florida, Washington University in St. Louis, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Memorial Sloan Kettering Cancer Center, Hebrew University of Jerusalem, Biokine (Israel), BioLineRx Ltd. (Israel)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2592251814